Maxim Group analyst Caroline Palomeque maintained a Buy rating on Brainstorm Cell Therapeutics (BCLI) today and set a price target of $9. The company’s shares opened today at $3.15, close to its 52-week low of $2.88.
Palomeque commented:
“Brainstorm announced that it has filed an IND with the FDA for NurOwn in a second indication, progressive multiple sclerosis (MS). The company plans to initiate a Phase 2 study for progressive MS, expanding NurOwn beyond amyotrophic lateral sclerosis (ALS, pivotal phase 3 ongoing).”
According to TipRanks.com, Palomeque has 0 stars on 0-5 star ranking scale with an average return of -13.6% and a 26.9% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics Inc, VistaGen Therapeutics, and Anavex Life Sciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Brainstorm Cell Therapeutics with a $10 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.35 and a one-year low of $2.88. Currently, Brainstorm Cell Therapeutics has an average volume of 55.17K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson’s disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.
